Trupanion, Inc. (NASDAQ:TRUP – Get Free Report) SVP Emily Dreyer sold 900 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $54.55, for a total transaction of $49,095.00. Following the transaction, the senior vice president now directly owns 23,808 shares in the company, valued at $1,298,726.40. The trade was a 3.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Emily Dreyer also recently made the following trade(s):
- On Friday, November 22nd, Emily Dreyer sold 3,100 shares of Trupanion stock. The shares were sold at an average price of $54.85, for a total transaction of $170,035.00.
Trupanion Trading Down 1.6 %
Shares of NASDAQ:TRUP opened at $53.50 on Thursday. The company has a market cap of $2.27 billion, a P/E ratio of -167.19 and a beta of 1.69. The stock’s 50-day moving average is $49.50 and its 200-day moving average is $39.97. Trupanion, Inc. has a 52-week low of $19.69 and a 52-week high of $57.90. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.66 and a current ratio of 1.66.
Wall Street Analysts Forecast Growth
Several research firms have commented on TRUP. Stifel Nicolaus boosted their target price on shares of Trupanion from $30.00 to $40.00 and gave the stock a “hold” rating in a research report on Monday, September 23rd. Bank of America boosted their target price on shares of Trupanion from $47.00 to $56.00 and gave the stock a “buy” rating in a research report on Friday, September 20th. Evercore ISI raised shares of Trupanion to a “strong-buy” rating in a research report on Friday, August 9th. Northland Securities boosted their target price on shares of Trupanion from $45.00 to $50.00 and gave the stock a “market perform” rating in a research report on Thursday, October 31st. Finally, Piper Sandler boosted their target price on shares of Trupanion from $45.00 to $57.00 and gave the stock a “neutral” rating in a research report on Thursday, October 31st. Three research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $44.67.
View Our Latest Research Report on TRUP
Institutional Investors Weigh In On Trupanion
A number of institutional investors have recently added to or reduced their stakes in TRUP. Wilmington Savings Fund Society FSB bought a new position in Trupanion during the third quarter worth about $54,000. Barclays PLC lifted its stake in Trupanion by 259.2% during the third quarter. Barclays PLC now owns 65,498 shares of the financial services provider’s stock worth $2,750,000 after purchasing an additional 47,262 shares during the period. DF Dent & Co. Inc. lifted its stake in Trupanion by 27.8% during the third quarter. DF Dent & Co. Inc. now owns 367,871 shares of the financial services provider’s stock worth $15,443,000 after purchasing an additional 80,014 shares during the period. Wellington Management Group LLP lifted its stake in Trupanion by 4.4% during the third quarter. Wellington Management Group LLP now owns 3,393,879 shares of the financial services provider’s stock worth $142,475,000 after purchasing an additional 142,156 shares during the period. Finally, Weiss Asset Management LP bought a new position in Trupanion during the third quarter worth about $855,000.
About Trupanion
Trupanion, Inc, together with its subsidiaries, provides medical insurance for cats and dogs on a monthly subscription basis in the United States, Canada, Continental Europe, and Australia. The company operates in two segments, Subscription Business and Other Business. It serves pet owners and veterinarians.
See Also
- Five stocks we like better than Trupanion
- Earnings Per Share Calculator: How to Calculate EPS
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- Top Biotech Stocks: Exploring Innovation Opportunities
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- 3 Healthcare Dividend Stocks to Buy
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Trupanion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trupanion and related companies with MarketBeat.com's FREE daily email newsletter.